Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

In this week's View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension.

Subscribe to Eagle's Eye View